Factor | Without hepatitis [cases (%)] | With hepatitis [cases (%)] | P value |
---|---|---|---|
Total | 144 | 21 | Â |
HBcAb | Â | Â | 0.013 |
 – | 101 (70.1) | 9 (42.9) |  |
 + | 43 (29.9) | 12 (57.1) |  |
HBeAb | Â | Â | 1.000 |
 – | 131 (91.0) | 19 (90.5) |  |
 + | 13 (9.0) | 2 (9.5) |  |
Age (years) | Â | Â | 0.399 |
 ≤60 | 62 (43.1) | 7 (33.3) |  |
 >60 | 82 (56.9) | 14 (66.7) |  |
Sex | Â | Â | 0.756 |
 Female | 60 (41.7) | 8 (38.1) |  |
 Male | 84 (58.3) | 13 (61.9) |  |
ECOG PS | Â | Â | 0.500 |
 0–1 | 125 (86.8) | 17 (81.0) |  |
 ≥2 | 19 (13.2) | 4 (19.0) |  |
B symptoms | Â | Â | 0.726 |
 − | 108 (75.0) | 15 (71.4) |  |
 + | 36 (25.0) | 6 (28.6) |  |
Ann Arbor stage†|  |  | 0.129 |
 I–II | 73 (50.7) | 7 (33.3) |  |
 III-IV | 70 (48.6) | 14 (66.7) |  |
Liver involvement | Â | Â | 0.598 |
 − | 136 (94.4) | 21 (100) |  |
 + | 8 (5.6) | 0 (0) |  |
Spleen involvement | Â | Â | 1.000 |
 − | 131 (91.0) | 19 (90.5) |  |
 + | 13 (9.0) | 2 (9.5) |  |
Involved extranodal sites | Â | Â | 0.586 |
 <2 | 111 (77.1) | 15 (71.4) |  |
 ≥2 | 33 (22.9) | 6 (28.6) |  |
Bone marrow involvement | Â | Â | 1.000 |
 − | 134 (93.1) | 20 (95.2) |  |
 + | 10 (6.9) | 1 (4.8) |  |
IPI score†|  |  | 0.180 |
 0–1 | 63 (43.8) | 6 (28.6) |  |
 2–5 | 80 (55.8) | 15 (71.4) |  |
ALT | Â | Â | 0.013 |
 ≤40 U/L | 128 (88.9) | 14 (66.7) |  |
 >40 U/L | 16 (11.1) | 7 (33.3) |  |
AST | Â | Â | 0.019 |
 ≤45 U/L | 131 (91.0) | 15 (71.4) |  |
 >45 U/L | 13 (9.0) | 6 (28.6) |  |
TB | Â | Â | 0.696 |
 ≤20.5 μmol/L | 129 (89.6) | 20 (95.2) |  |
 >20.5 μmol/L | 15 (10.4) | 1 (4.8) |  |
LDH | Â | Â | 0.728 |
 ≤245 U/mL | 88 (61.1) | 12 (57.1) |  |
 >245 U/mL | 56 (38.9) | 9 (42.9) |  |